TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR SKIN REPLACEMENTS AND SUBSTITUTES

118 Pages | 20 Exhibits | 2010 Analysis | Forecasts Through 2014

OVERVIEW:
Skin replacements and substitute products currently represent one of the most promising applications of tissue engineering. In 2009, the potential United States (U.S.) market for tissue-engineered skin replacements and substitutes totaled approximately $18.9 billion, based on a target patient population of approximately 5.0 million. By the year 2019, the total potential target population for the use of tissue-engineered skin replacements and substitutes is expected to increase to 6.4 million, resulting in a potential U.S. market of approximately $24.3 billion in the year 2019. The largest potential area of this market is represented by products for the treatment of diabetic, pressure, and venous ulcers; followed by products for abdominal wall repair, then products for other applications (e.g., dermabrasion site treatment products, fasciotomy site treatment products, Mohs surgery site treatment products, skin graft donor site treatment products, and traumatic wound repair products); and products for burn treatment; face, head, and neck reconstruction; and breast augmentation/repair.

This newest report from Medtech Insight provides the U.S. market forecast for tissue-engineered skin replacement and substitute products for the years 2009 to 2014, an estimation of the potential market for the years 2009 and 2019, and a competitive analysis (including market shares for the leading suppliers to this market). In addition, this new report also provides an overview of tissue-engineered skin replacement and substitutes currently being marketed in the U.S., an update on emerging products as well as a clinical overview of the primary clinical applications for tissue-engineered skin replacements and substitutes (including up-to-date incidence and prevalence numbers for associated diseases).

This is the final report in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. Previous reports in this series have provided analyses of the U.S. markets for cardiac and vascular, musculoskeletal, neurosurgical, urologic, and organ regeneration tissue engineering and cell transplantation products.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Selected Clinical Applications for Skin Replacements and Substitutes 
	a. Burns 
	b. Skin Ulcers 
	c. Plastic Surgery 
	d. Inguinal Herniorrhaphy 
ii. Tissue Engineering Technologies 
	a. Biomaterials 
	b. Cell Culture Technology 
	c. Stem Cell Technology 
	d. Immunoisolation Technology 
iii. Skin Replacement and Substitute Products 
iv. Market Analysis 
	a. Market Drivers 
	b. Market Limiters 
v. Methodology 

Exhibit ES-1: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures 
Exhibit ES-2: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019 
Exhibit ES-3: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014 

1. CLINICAL OVERVIEW

1.1 Layers of the Skin and Supporting Structures 
	1.1.1 Epidermis 
	1.1.2 Dermis 
	1.1.3 Subcutaneous Tissue 
	1.1.4 Fascia 
	1.1.5 Muscle 
	1.1.6 Bone 
1.2 Selected Clinical Applications for Skin Replacements and Substitutes 
	1.2.1 Burns 
	1.2.2 Skin Ulcers 
		1.2.2.1 Diabetic Ulcers 
		1.2.2.2 Pressure Ulcers 
		1.2.2.3 Venous Stasis Ulcers 
	1.2.3 Plastic Surgery 
	1.2.4 Inguinal Herniorrhaphy 

Exhibit 1-1: The Skin's Layers and Supporting Structures 
Exhibit 1-2: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures 
Exhibit 1-3: Stages of Burn Wounds 
Exhibit 1-4: Stages of Pressure Ulcers 
Exhibit 1-5: National Nursing Home Survey Regarding Pressure Ulcers 

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

2.1 Biomaterials 
	2.1.1 Synthetic Biomaterials 
	2.1.2 Biologically Derived Biomaterials 
		2.1.2.1 Collagen 
		2.1.2.2 Xenogeneic Tissue 
	2.1.3 Hybrid Biomaterials 
	2.1.4 Genetically Engineered Biomaterials 
		2.1.4.1 Deoxyribonucleic Acid Transfection Vectors 
		2.1.4.2 Genetically Manipulated Cells 
		2.1.4.3 Three-Dimensional Polymer Technology 
		2.1.4.4 Transgenics 
		2.1.4.5 Fibroblasts 
		2.1.4.6 Immortalized Neural Stem Cells 
		2.1.4.7 Gene-Activated Matrices 
	2.1.5 Scaffolds 
	2.1.6 Vascular Grafts 
2.2 Cell Culture Technology 
	2.2.1 Bioreactors 
		2.2.1.1 Flatbed Perfusion Systems 
		2.2.1.2 Hollow Fiber Bioreactor Systems 
		2.2.1.3 Cell Suspension Systems 
		2.2.1.4 Disposable Bioreactors 
2.3 Stem Cell Technology 
	2.3.1 Cell Extraction and Expansion 
	2.3.2 Bioreactors 
2.4 Immunoisolation Technology 
	2.4.1 Chimeric Immunity 
	2.4.2 Cell Encapsulation Technology 

Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering 
Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering 
Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 
 
3. U.S. MARKETS FOR TISSUE-ENGINEERED SKIN REPLACEMENTS AND SUBSTITUTES

3.1 Allografts 
3.2 Autografts 
3.3 Xenografts 
3.4 Amniotic Membranes 
3.5 Skin Replacement and Substitute Products 
	3.5.1 Epidermal Equivalents 
	3.5.2 Dermal Equivalents 
	3.5.3 Composite Bilayer Skin Equivalents 
	3.5.4 Other Biological Products for Wound Care 
3.6 Emerging Skin Replacement and Substitute Products 
	3.6.1 Emerging Epidermal Equivalents 
	3.6.2 Emerging Composite Bilayer Skin Equivalents 
	3.6.3 Other Emerging Biological Products for Wound Care 
3.7 Market Analysis 
	3.7.1 Market Drivers 
	3.7.2 Market Limiters 
3.8 Competitive Analysis 

Exhibit 3-1: Advantages and Disadvantages of Allografts 
Exhibit 3-2: 2010, Selected Dermal Equivalent Skin Substitutes 
Exhibit 3-3: 2010, Selected Composite Bilayer Equivalent Skin Substitutes 
Exhibit 3-4: 2010, Selected Emerging Epidermal Equivalent Products 
Exhibit 3-5: 2010, Selected Emerging Composite Bilayer Equivalent Products 
Exhibit 3-6: 2010, Selected Other Emerging Biological Wound Repair Products 
Exhibit 3-7: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019 
Exhibit 3-8: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014 
Exhibit 3-9: 2009, Tissue Engineered Skin Replacements and Substitutes Market, Share by Supplier 

4. COMPANY PROFILES

4.1 Advanced BioHealing, Inc. 
4.2 Cook Biotech, Inc./Cook Group, Inc. 
4.3 Cytomedix, Inc. 
4.4 Integra LifeSciences Corporation 
4.5 LifeCell Corporation/Kinetic Concepts, Inc. 
4.6 Organogenesis, Inc. 
4.7 Soluble Systems LLC 
4.8 Stemnion, Inc. 
4.9 TEI Biosciences, Inc. 
4.10 Wright Medical Group, Inc. 

APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Advanced BioHealing, Inc.
  2. Cook Biotech, Inc./Cook Group, Inc.
  3. Cytomedix, Inc.
  4. Integra LifeSciences Corporation
  5. LifeCell Corporation/Kinetic Concepts, Inc.
  6. Organogenesis, Inc.
  7. Soluble Systems LLC
  8. Stemnion, Inc.
  9. TEI Biosciences, Inc.
  10. Wright Medical Group, Inc.
Contact Us

Need help finding medtech research? Let us help you!